Bahman Yousefi

Dr. Bahman Yousefi

Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in DNA Repair
Verified
Journal Article
Closed access
AKAnsar Karimian
Ansar Karimian
YAYasin Ahmadi
Yasin Ahmadi
BYBahman Yousefi
Bahman Yousefi

1 January 2020 in Biotechnology Advances
Verified
Journal Article
Closed access
Seyed Mohammad NabaviSeyed Mohammad Nabavi
Seyed Mohammad Nabavi
Dunja ŠamecDunja Šamec
Dunja Šamec
Michał TomczykMichał Tomczyk
Michał Tomczyk
LMLuigi Milella
Luigi Milella
DRDaniela Russo
Daniela Russo
SSSamira Shirooie
Samira Shirooie

3 August 2017 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MMMaryam Majidinia
Maryam Majidinia
ASAlireza Sadeghpour
Alireza Sadeghpour
BYBahman Yousefi
Bahman Yousefi

27 February 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
SRSetareh Rezatabar
Setareh Rezatabar
AKAnsar Karimian
Ansar Karimian
VRVahid Rameshknia
Vahid Rameshknia
HPHadi Parsian
Hadi Parsian
MMMaryam Majidinia
Maryam Majidinia
BYBahman Yousefi
Bahman Yousefi

1 April 2019 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
ZAZahra Aghapour
Zahra Aghapour
PGPourya Gholizadeh
Pourya Gholizadeh
KGKhudaverdi Ganbarov
Khudaverdi Ganbarov
ABAbed Zahedi bialvaei
Abed Zahedi bialvaei
SMSuhad Saad Mahmood
Suhad Saad Mahmood
Hossein Samadi KafilHossein Samadi Kafil
Hossein Samadi Kafil
Colistin is an effective antibiotic for treatment of most multidrug-resistant Gram-negative bacteria. It is used currently as a last-line drug for infections due to severe Gram-negative bacteria followed by an increase in resistance among Gram-negative bacteria. Colistin resistance is considered a serious problem, due to a lack of alternative antibiotics. Some bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacteriaceae members, such as Escherichia coli, Salmonella spp., and Klebsiella spp. have an acquired resistance against colistin. However, other bacteria, including Serratia spp., Proteus spp. and Burkholderia spp. are naturally resistant to this antibiotic. In addition, clinicians should be alert to the possibility of colistin resistance among multidrug-resistant bacteria and development through mutation or adaptation mechanisms. Rapidly emerging bacterial resistance has made it harder for us to rely completely on the discovery of new antibiotics; therefore, we need to have logical approaches to use old antibiotics, such as colistin. This review presents current knowledge about the different mechanisms of colistin resistance.

3 January 2022 in Cellular & Molecular Biology Letters
Verified
Journal Article
Open access
PDF file
PDParisa Maleki Dana
Parisa Maleki Dana
FSFatemeh Sadoughi
Fatemeh Sadoughi
ZAZatollah Asemi
Zatollah Asemi
BYBahman Yousefi
Bahman Yousefi
Chemotherapeutic drugs are used to treat advanced stages of cancer or following surgery. However, cancers often develop resistance against drugs, leading to failure of treatment and recurrence of the disease. Polyphenols are a family of organic compounds with more than 10,000 members which have a three-membered flavan ring system in common. These natural compounds are known for their beneficial properties, such as free radical scavenging, decreasing oxidative stress, and modulating inflammation. Herein, we discuss the role of polyphenols (mainly curcumin, resveratrol, and epigallocatechin gallate [EGCG]) in different aspects of cancer drug resistance. Increasing drug uptake by tumor cells, decreasing drug metabolism by enzymes (e.g. cytochromes and glutathione-S-transferases), and reducing drug efflux are some of the mechanisms by which polyphenols increase the sensitivity of cancer cells to chemotherapeutic agents. Polyphenols also affect other targets for overcoming chemoresistance in cancer cells, including cell death (i.e. autophagy and apoptosis), EMT, ROS, DNA repair processes, cancer stem cells, and epigenetics (e.g. miRNAs).